Our Approach

The RARE IMPACT initiative aims to identify and validate the challenges to patients’ access to gene and cell therapies through engagement with HTA agencies, regulatory bodies, payers, patient groups, clinicians, manufacturers and other experts across Europe.

The perspective of patients and decision-makers – the ultimate users of gene and cell therapies – is a cornerstone of this unique initiative. The consortium will liaise with the European Reference Networks (ERNs), Health Technology Assessment (HTA) Network and the European Medicines Agency (EMA) to align the activities.